BRCA1 Antibody (RAY) - BSA Free

BRCA1 (breast cancer early-onset 1) is a tumour-suppressor gene which was originally discovered on the basis of its linkage to early-onset breast or ovarian cancer in women. BRCA1 gene encodes a protein of 1863 amino acids with three distinct regions of protein interaction: RING domain, RAD51-interaction domain and BRCT (BRCA1 C-terminus) domain. The N-terminal RING finger domain binds to several proteins, including formation of heterodimers with BARD1 (BRCA1-associated RING domain protein). Both BRCA1 and BARD1 contain the RING finger domain which is important for tumour-suppression functions. The RAD51-interaction domain is enclosed by exon 11 and is involved in DNA-DSBs repair. It also contains multiple protein-binding sites, in addition to those for RAD51/RAD50 complex. Loss of RAD51 binding increase the risk of cancer as there could be an increment in the amount of damaged DNA. The C-terminus of BRCA1 contains an acidic domain that functions as a transcriptional activation domain and this domain contains a tandem repeat of approximately 95 amino acids called BRCT. This domain is also found in proteins such as BARD1 which is involved in cell-cycle control and DNA repair. BRCA1 has been implicated in diverse cancer-related activities, including roles in cell-cycle progression, DNA repair, DNA damage-responsive cell-cycle checkpoints, transcription regulation, ubiquitination, chromosome remodelling and apoptosis. Defects in BRCA1 are a cause of susceptibility to breast cancer, familial breast-ovarian cancer type 1 (BROVCA1), ovarian cancer, and pancreatic cancer type 4 (PNCA4).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 3 applications: FLOW, ICC/IF, WB.

Showing Publications 1 - 6 of 6.

Publications using NB100-598	Applications	Species
Kostyuk SV, Ershova ES, Martynov AV et al. In Vitro Analysis of Biological Activity of Circulating Cell-Free DNA Isolated from Blood Plasma of Schizophrenic Patients and Healthy Controls-Part 2: Adaptive Response Genes 2022-12-04 [PMID: 36553550] (FLOW, Human)	FLOW	Human
Gon�alves AB, Hasselbalch SK, Joensen BB et al. CEP78 functions downstream of CEP350 to control biogenesis of primary cilia by negatively regulating CP110 levels eLife 2021-07-14 [PMID: 34259627]
Vanderperre B, Lucier JF, Bissonnette C et al. Direct Detection of Alternative Open Reading Frames Translation Products in Human Significantly Expands the Proteome. PLoS One. 2013-08-12 [PMID: 23950983] (ICC/IF, Human)	ICC/IF	Human
Kluk BJ, Fu Y, Formolo TA et al. BP1, an isoform of DLX4 homeoprotein, negatively regulates BRCA1 in sporadic breast cancer. Int J Biol Sci 2010-09-10 [PMID: 20877436] (WB, Human)	WB	Human
Yin J, Wei ZJ, Li KB et al. Identification and molecular characterization of a new member of the peritrophic membrane proteins from the meadow moth, loxostege sticticalis. Int J Biol Sci;6(5):491-8. 2010-09-06 [PMID: 20827401]
Okada S, Ouchi T. Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. J Biol Chem 2003-01-01 [PMID: 12427729]

Array NB100-598

• BRCA1 Antibodies
• BRCA1 Antibody Pack
• BRCA1 ELISA Kits
• BRCA1 Proteins